MRKMerck Sharp & Dohme LLCRunning, no new patients
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Gastrointestinal Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 180 (planned)
- Started
- Nov 3, 2024
- Main results expected
- Dec 7, 2028
- Fully finished
- Dec 7, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Experiencing Dose-Limiting Toxicity (DLT) (Dose-Escalation Phase)
Measured over: Up to 21 days
Number of Participants with One or More Adverse Events (AEs)
Measured over: Up to approximately 44 months
Number of Participants who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 44 months
Objective Response Rate (ORR)
Measured over: Up to approximately 44 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06596694 · record last updated 2026-10-02 · checked 2026-11-09 15:47 UTC